- Home
- PDFS vs GHRS Comparison
PDFS vs GHRS Comparison
Compare PDFS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDFS
- GHRS
- Stock Information
- Founded
- PDFS 1992
- GHRS 2018
- Country
- PDFS United States
- GHRS Ireland
- Employees
- PDFS N/A
- GHRS N/A
- Industry
- PDFS EDP Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- PDFS Technology
- GHRS Health Care
- Exchange
- PDFS Nasdaq
- GHRS Nasdaq
- Market Cap
- PDFS 668.1M
- GHRS 583.1M
- IPO Year
- PDFS N/A
- GHRS 2021
- Fundamental
- Price
- PDFS $18.41
- GHRS $10.60
- Analyst Decision
- PDFS Strong Buy
- GHRS Strong Buy
- Analyst Count
- PDFS 3
- GHRS 8
- Target Price
- PDFS $33.33
- GHRS $30.63
- AVG Volume (30 Days)
- PDFS 209.9K
- GHRS 146.4K
- Earning Date
- PDFS 05-08-2025
- GHRS 05-08-2025
- Dividend Yield
- PDFS N/A
- GHRS N/A
- EPS Growth
- PDFS N/A
- GHRS N/A
- EPS
- PDFS 0.03
- GHRS N/A
- Revenue
- PDFS $185,933,000.00
- GHRS N/A
- Revenue This Year
- PDFS $18.10
- GHRS N/A
- Revenue Next Year
- PDFS $18.98
- GHRS N/A
- P/E Ratio
- PDFS $617.25
- GHRS N/A
- Revenue Growth
- PDFS 11.75
- GHRS N/A
- 52 Week Low
- PDFS $15.91
- GHRS $6.00
- 52 Week High
- PDFS $39.70
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- PDFS 46.27
- GHRS 59.36
- Support Level
- PDFS $18.60
- GHRS $9.81
- Resistance Level
- PDFS $19.89
- GHRS $11.50
- Average True Range (ATR)
- PDFS 0.79
- GHRS 0.72
- MACD
- PDFS 0.23
- GHRS 0.23
- Stochastic Oscillator
- PDFS 49.49
- GHRS 89.60
About PDFS PDF Solutions Inc.
PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.